Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine with Adjuvant PF-07872411 in Adults 50-64
NCT05831124Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2023
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of multivalent pneumococcal conjugate vaccine + PF-07872411 in pneumococcal disease (4 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting local reactions at 7 days, Percentage of participants reporting systemic events at 7 days and 5 more. Started Apr 2023; status: completed.
02
Drugs
multivalent pneumococcal conjugate vaccine + PF-07872411
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05831124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831124.